Small Molecule Antagonists of PF4 for the Treatment and Prevention of HIT

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R41HL123126-01
Agency Tracking Number: R41HL123126
Amount: $225,000.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NHLBI
Solicitation Number: PA13-235
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
3805 OLD EASTON RD, DOYLESTOWN, PA, 18902-8400
DUNS: 828761002
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 (215) 898-0568
Business Contact
Phone: (215) 589-6435
Research Institution
 Office of Research Services
3451 Walnut Street P-221 Franklin Building
PHILADELPHIA, PA, 19104-6205
 () -
 Nonprofit college or university
We have discovered the first-ever inhibitors of PF4, a platelet protein central to the pathophysiology of heparin induced thrombocytopenia (HIT). Heparin is a naturally-occurring anticoagulant that prevents the formation of clots and extension of existingclots within the vasculature, and major medical applications of heparin include dialysis, cardiac catheterization, and cardiopulmonary bypass surgery. Heparin therapy is usually safe and effective; however some patients develop HIT as a serious complication caused by an immunological reaction that targets platelets leading to a low platelet count (thrombocytopenia). HIT increases the risk of blood clots forming within blood vessels and blocking the flow of blood (thrombosis), referred to as HITT when thrombosis occurs. HITT develops in approximately 1-3% of patients treated with heparin for 5-10 days. Affected individuals have a 20-50% risk of developing new thromboembolic events, a mortality rate ~20%, and an additional ~10% of patients require amputations

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government